{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:07:19Z","timestamp":1787069239818,"version":"build-2736575974"},"reference-count":43,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Isotretinoin is a highly effective treatment for moderate-to-severe acne, but strict contraceptive measures are required because of its teratogenicity. The European Pregnancy Prevention Programme (PPP) aims to minimise foetal exposure through structured protocols. However, real-world data on patient compliance and treatment outcomes are limited. Methods: This retrospective study included 569 female patients aged 14\u201325 years treated with isotretinoin in Poland (2021\u20132022). Patients were assigned to three groups based on PPP compliance: full (Group I), partial (Group IIA), and minimal (Group IIB). Data on contraception, cumulative dose, treatment duration, adverse events, laboratory monitoring, and therapy discontinuation were analysed using non-parametric statistical tests (p &lt; 0.05). Results: No pregnancies occurred during treatment. Overall compliance with PPP requirements was high: 100% of the patients used contraception or declared abstinence. The majority (92.79%) used condoms, 1.93% used oral contraceptives, and 7.21% reported abstinence. Significant differences in cumulative isotretinoin dose were observed between the groups (Kruskal\u2013Wallis H = 19.89, p &lt; 0.001), with Group I receiving a lower mean dose than those in Groups IIA (p &lt; 0.001) and IIB (p &lt; 0.01). Notably, all therapy discontinuations (4.75%) occurred in Group I (full compliance), which may reflect stricter monitoring and an earlier identification of adverse effects or patient concerns. These discontinuations were associated with lower cumulative dosing (Mann\u2013Whitney Z = 7.81, p &lt; 0.001) than that seen in the other groups. An inverse correlation between age and cumulative dose was also found (H = 13.09, p = 0.0004), with younger patients (\u226417 years) more likely to reach therapeutic targets. Conclusions: Isotretinoin therapy under structured PPP protocols is safe and effective, with no pregnancies reported and excellent contraceptive compliance. Significant differences in dosing and adherence patterns highlight the need for flexible patient-centred approaches to optimise safety and outcomes.<\/jats:p>","DOI":"10.3390\/jcm14103497","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T10:24:02Z","timestamp":1747391042000},"page":"3497","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Compliance with the European Pregnancy Prevention Programme in Isotretinoin Treatment: Safety Outcomes and Dose-Related Correlations"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6817-606X","authenticated-orcid":false,"given":"Piotr","family":"Brzezi\u0144ski","sequence":"first","affiliation":[{"name":"Institute of Health Sciences, Pomeranian University in S\u0142upsk, 76-200 S\u0142upsk, Poland"},{"name":"Department of Dermatology, Voivodeship Specialist Hospital, 76-200 S\u0142upsk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0719-1754","authenticated-orcid":false,"given":"Igor Jaros\u0142aw","family":"Feszak","sequence":"additional","affiliation":[{"name":"Institute of Health Sciences, Pomeranian University in S\u0142upsk, 76-200 S\u0142upsk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"\u015amigielski","sequence":"additional","affiliation":[{"name":"State School of Higher Professional Education in Konin, 62-510 Konin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3902-2744","authenticated-orcid":false,"given":"Piotr","family":"Kawczak","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Gda\u0144sk, 80-416 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6468-1974","authenticated-orcid":false,"given":"Tomasz","family":"B\u0105czek","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Gda\u0144sk, 80-416 Gda\u0144sk, Poland"},{"name":"Department of Nursing and Medical Rescue, Institute of Health Sciences, Pomeranian University in S\u0142upsk, 76-200 S\u0142upsk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1006.e1","DOI":"10.1016\/j.jaad.2023.12.017","article-title":"Guidelines of care for the management of acne vulgaris","volume":"90","author":"Reynolds","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4103\/ejdv.ejdv_68_23","article-title":"Inflammatory biomarkers and clinical adverse effects associated with Isotretinoin treatment: A prospective study","volume":"44","author":"Nofal","year":"2024","journal-title":"Egypt. J. Dermatol. Venerol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/17512433.2020.1796637","article-title":"The Use of Isotretinoin for Acne\u2014An Update on Optimal dosing, surveillance, and Adverse Effects","volume":"13","author":"Bagatin","year":"2020","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.7241\/ourd.20221.23","article-title":"Progress of different treatment modalities to limit the use of antibiotics in the treatment of acne","volume":"13","author":"Sanjel","year":"2022","journal-title":"Our Dermatol. Online"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"230","DOI":"10.7241\/ourd.2023cme.1","article-title":"Acne mimickers: Differential diagnosis of open comedones: A short review","volume":"14","author":"Soundarya","year":"2023","journal-title":"Our Dermatol. Online"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"417","DOI":"10.7241\/ourd.20214.14","article-title":"Rapid-onset oral isotretinoin-induced acne fulminans without systemic symptoms in a male adolescent","volume":"12","year":"2021","journal-title":"Our Dermatol. Online"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.2147\/CCID.S481939","article-title":"Rosacea Fulminans in Pregnancy: A Case Report and Review","volume":"17","author":"Yao","year":"2024","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Melnik, B.C. (2023). Acne Transcriptomics: Fundamentals of Acne Pathogenesis and Isotretinoin Treatment. Cells, 12.","DOI":"10.20944\/preprints202310.0472.v1"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"s34","DOI":"10.7861\/clinmedicine.16-3-s34","article-title":"Efficacy and relapse rates of different Isotretinoin dosages in treating acne vulgaris: Systemic review","volume":"16","author":"Tan","year":"2016","journal-title":"Clin. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/ced\/llae395","article-title":"Bibliometric analysis of studies investigating the association between isotretinoin use and depression and suicide","volume":"50","year":"2025","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Kawczak, P., Feszak, I., Brzezi\u0144ski, P., and B\u0105czek, T. (2024). Structure-Activity Relationships and Therapeutic Applications of Retinoids in View of Potential Benefits from Drug Repurposing Process. Biomedicines, 12.","DOI":"10.3390\/biomedicines12051059"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.21608\/ejhm.2024.374386","article-title":"Most Common Isotretinoin Therapy Side Effects on Egyptian Acne Females in Dakahlia Governorate","volume":"96","author":"Mahsoub","year":"2024","journal-title":"Egypt. J. Hosp. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7241\/ourd.2020S3.1","article-title":"An investigation of the effects of acitretin on erectile function","volume":"11","author":"Topal","year":"2020","journal-title":"Our Dermatol. Online"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.7241\/ourd.20231.4","article-title":"Severity of acne and quality of life of patients treated at Cameroonian hospitals (sub-Saharan Africa)","volume":"14","author":"Kouotou","year":"2023","journal-title":"Our Dermatol. Online"},{"key":"ref_15","first-page":"e50516","article-title":"Knowledge, Attitude, and Practice Regarding the Use of Isotretinoin in Saudi Arabia","volume":"15","author":"Alghamdi","year":"2023","journal-title":"Cureus"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1440-0960.2012.00947.x","article-title":"Isotretinoin: Dose, duration and relapse. What does 30 years of usage tell us?","volume":"54","author":"Rademaker","year":"2013","journal-title":"Australas. J. Dermatol."},{"key":"ref_17","first-page":"e69390","article-title":"The Perception of Contraceptive Practice Among Female Patients Treated with Isotretinoin in Saudi Arabia","volume":"16","author":"Almarri","year":"2024","journal-title":"Cureus"},{"key":"ref_18","first-page":"e58840","article-title":"Prescribing Patterns of Isotretinoin for Acne Among Dermatologists in Central Jordan","volume":"16","author":"Alshiyab","year":"2024","journal-title":"Cureus"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jamadermatol.2019.1388","article-title":"US Food and Drug Administration Reports of Pregnancy and Pregnancy-Related Adverse Events Associated with Isotretinoin","volume":"155","author":"Tkachenko","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jaad.2010.09.017","article-title":"The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system","volume":"65","author":"Shin","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2020.02.022","article-title":"Simplifying contraception requirements for iPLEDGE: A decision analysis","volume":"83","author":"Barbieri","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Dur\u00e1n, C.E., Riera-Arnau, J., Abtahi, S., Pajouheshnia, R., Hoxhaj, V., Gamba, M., Alsina, E., Martin-Perez, M., Garcia-Poza, P., and Llorente-Garcia, A. (2023). Impact of the 2018 revised Pregnancy Prevention Programme by the European Medicines Agency on the use of oral retinoids in females of childbearing age. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1207976"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40801-023-00381-3","article-title":"Compliance with Pregnancy Prevention Recommendations for Isotretinoin Following the Amendment of the European Union Pregnancy Prevention Program: A Repeat Study in Estonia","volume":"11","author":"Ivask","year":"2024","journal-title":"Drugs Real World Outcomes"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/jdv.20073","article-title":"Compliance with the pregnancy prevention program among women initiating isotretinoin treatment between 2014 and 2021: A nationwide cohort study on the French Health Data System (SNDS)","volume":"39","author":"Havet","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archderm.142.8.1016","article-title":"A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris","volume":"142","author":"Zane","year":"2006","journal-title":"Arch. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris","volume":"74","author":"Zaenglein","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1007\/s10815-022-02606-w","article-title":"Early \u03b2-hCG levels predict live birth after single embryo transfer","volume":"39","author":"Hughes","year":"2022","journal-title":"J. Assist. Reprod. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e35605","DOI":"10.1097\/MD.0000000000035605","article-title":"Initial \u03b2-hCG levels and 2-day-later increase rates effectively predict pregnancy outcomes in single blastocyst transfer in frozen-thawed or fresh cycles: A retrospective cohort study","volume":"102","author":"Ozer","year":"2023","journal-title":"Medicine"},{"key":"ref_29","first-page":"17","article-title":"Face to face with oral isotretinoin: A closer look at the spectrum of therapeutic outcomes and why some patients need repeated courses","volume":"5","year":"2012","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e12483","DOI":"10.1111\/dth.12483","article-title":"Adverse effects of isotretinoin: A large, retrospective review","volume":"30","author":"Brzezinski","year":"2017","journal-title":"Dermatol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Jakobi, A.U., Bircher, A.J., Pagnamenta, A., and Terrani, I. (2025). Isotretinoin Concerns in Switzerland: A Student-Based Transversal Study. J. Clin. Med., 14.","DOI":"10.3390\/jcm14061801"},{"key":"ref_32","unstructured":"Hebebrand, M. (2025, May 13). Isotretinoin Often Continued Despite Mood Concerns, Dermatology Times. Available online: https:\/\/www.dermatologytimes.com\/view\/isotretinoin-often-continued-despite-mood-concerns."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/pds.3763","article-title":"Compliance with pregnancy prevention plan recommendations in 8672 French women of childbearing potential exposed to acitretin","volume":"24","author":"Raguideau","year":"2015","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_34","unstructured":"British Association of Dermatologists (2019). Guidelines for Isotretinoin Use and Monitoring, BAD."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1111\/ijd.17225","article-title":"Risk and timing of isotretinoin-related laboratory disturbances: A population-based study","volume":"63","author":"Emtenani","year":"2024","journal-title":"Int. J. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/dth.12084","article-title":"Isotretinoin updates","volume":"26","author":"On","year":"2013","journal-title":"Dermatol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/jamadermatol.2013.6862","article-title":"Women\u2019s experiences with isotretinoin risk reduction counseling","volume":"150","author":"Werner","year":"2014","journal-title":"JAMA Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaad.2019.06.025","article-title":"The clinical utility of laboratory monitoring during isotretinoin therapy for acne and changes to monitoring practices over time","volume":"82","author":"Barbieri","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2301435","DOI":"10.1080\/09546634.2023.2301435","article-title":"A novel predictive method for risk stratification in acne patients receiving isotretinoin: An analysis of laboratory abnormalities and changes in inflammatory parameters","volume":"35","author":"Murshidi","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/pds.3481","article-title":"Concomitant use of isotretinoin and contraceptives before and after iPledge in the United States","volume":"22","author":"Pinheiro","year":"2013","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00404-009-1112-2","article-title":"Isotretinoin exposure and pregnancy outcome: An observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy","volume":"281","author":"Schaefer","year":"2010","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/pds.4441","article-title":"Evaluation of compliance with isotretinoin PPP recommendations and exploration of reasons for non-compliance: Survey among French-speaking health care professionals and patients in Belgium","volume":"27","author":"Lelubre","year":"2018","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1080\/02664763.2020.1793307","article-title":"A new bivariate Poisson distribution via conditional specification: Properties and applications","volume":"48","author":"Ghosh","year":"2020","journal-title":"J. Appl. Stat."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/10\/3497\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:34:08Z","timestamp":1760031248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/10\/3497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":43,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["jcm14103497"],"URL":"https:\/\/doi.org\/10.3390\/jcm14103497","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]}}}